Evidence map›Paper›PMID 38214751›Full record

ArticleCellular and molecular life sciences : CMLS2024

Overexpressing lipid raft protein STOML2 modulates the tumor microenvironment via NF-κB signaling in colorectal cancer.

Hui Gong, Shaojing Chen, Shuguang Liu, Qianying Hu, Yixuan Li, Yifan Li, Guiqiu Li, Kaimeng Huang, Riqing Li, Lishan Fang

Open access · goldAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Hui Gong *Clinical Laboratory, Huazhong University of Science and Technology Union Shenzhen Hospital/Shenzhen Nanshan People's Hospital/The 6th Affiliated Hospital of Shenzhen University Medical School, Shenzhen, 518052, Guangdong, China.
Shaojing Chen *Medical Research Center, The Eighth Affiliated Hospital, Sun Yat-Sun University, Shenzhen, 518033, China.
Shuguang Liu *Department of Pathology, The Eighth Affiliated Hospital, Sun Yat-Sun University, Shenzhen, 518033, China.
Qianying Hu *Medical Research Center, The Eighth Affiliated Hospital, Sun Yat-Sun University, Shenzhen, 518033, China.
Yixuan LiMedical Research Center, The Eighth Affiliated Hospital, Sun Yat-Sun University, Shenzhen, 518033, China.
Yifan LiClinical Laboratory, Huazhong University of Science and Technology Union Shenzhen Hospital/Shenzhen Nanshan People's Hospital/The 6th Affiliated Hospital of Shenzhen University Medical School, Shenzhen, 518052, Guangdong, China.
Guiqiu LiClinical Laboratory, Huazhong University of Science and Technology Union Shenzhen Hospital/Shenzhen Nanshan People's Hospital/The 6th Affiliated Hospital of Shenzhen University Medical School, Shenzhen, 518052, Guangdong, China. lgq7566@126.com.
Kaimeng HuangDivision of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA. Kaimeng_huang@dfci.Harvard.edu.
Riqing LiShenzhen Agricultural Technology Promotion Center, Shenzhen, 518005, China. liriqing246@163.com.
Lishan FangMedical Research Center, The Eighth Affiliated Hospital, Sun Yat-Sun University, Shenzhen, 518033, China. fanglsh5@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-0183-861X
Sun Yat-sen University · CNShenzhen University · CNHarvard University · USShenzhen Technology University · CN

Funding

Eighth Affiliated Hospital of Sun Yat-sen University Outstanding Medical Innovation Talents YXYXCXRC202105Fundamental Research Funds for the Central Universities 18ykpy28Futian Healthcare Research Project FTWS2023057Huazhong University of Science and Technology Union Shenzhen Hospital Funds YN2022013Huazhong University of Science and Technology Union Shenzhen Hospital Funds YN2022017Nanshan District Health System Major Science and Technology Project NSZD2023015Nanshan District Health System Major Science and Technology Project NSZD2023029National Natural Science Foundation of China 81402310National Natural Science Foundation of China 81672957National Natural Science Foundation of China 81902885National Natural Science Foundation of China 82203671National Natural Science Foundation of China 82372913Natural Science Foundation of Guangdong Province 2017A030313761Natural Science Foundation of Guangdong Province 2020A1515011303Natural Science Foundation of Guangdong Province 2022A1515012172Shenzhen Futian District Health Public Welfare Research Project FTWS2020074Shenzhen Nanshan Science and Technology Research Funds NS2022018Shenzhen Science and Technology Innovation Program JCYJ20210324115205014Shenzhen Science and Technology Innovation Program JCYJ20220530144405013
6 · The paper itself

Abstract

Colorectal cancer (CRC) is characterized by a complex tumor inflammatory microenvironment, while angiogenesis and immunosuppression frequently occur concomitantly. However, the exact mechanism that controls angiogenesis and immunosuppression in CRC microenvironment remains unclear. Herein, we found that expression levels of lipid raft protein STOML2 were increased in CRC and were associated with advanced disease stage and poor survival outcomes. Intriguingly, we revealed that STOML2 is essential for CRC tumor inflammatory microenvironment, which induces angiogenesis and facilitates tumor immune escape simultaneously both in vitro and in vivo. Moreover, tumors with STOML2 overexpression showed effective response to anti-angiogenesis treatment and immunotherapy in vivo. Mechanistically, STOML2 regulates CRC proliferation, angiogenesis, and immune escape through activated NF-κB signaling pathway via binding to TRADD protein, resulting in upregulation of CCND1, VEGF, and PD-L1. Furthermore, treatment with NF-κB inhibitor dramatically reversed the ability of proliferation and angiogenesis. Clinically, we also observed a strong positive correlation between STOML2 expression and Ki67, CD31, VEGFC and PD-1 of CD8

Indexed as

Colorectal NeoplasmsMembrane ProteinsNF-kappa BTumor MicroenvironmentBlood ProteinsCell Line, TumorHumansMembrane MicrodomainsSignal TransductionUp-RegulationBlood ProteinsMembrane ProteinsNF-kappa BSTOML2 protein, humanAngiogenesisColorectal cancerLipid raftsNF-κBSTOML2Tumor microenvironment

Identifiers

PMID38214751
PMCPMC10786741
OpenAlexW4390794157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.